Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (381-390 of 436) with videos related to

Pageof 44
Sort By:
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
The Journal of Rheumatology|March 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working GroupYing Ying Leung, Ana-Maria Orbai, William Tillett, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
The Journal of Rheumatology|December 17, 2018
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical TrialsAna-Maria Orbai, Richard Holland, Ying Ying Leung, et al.
Seminars in Arthritis and Rheumatism|September 8, 2021
Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 processDavid Roofeh, Shaney L Barratt, Athol U Wells, et al.
Annals of the Rheumatic Diseases|September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
The Journal of Rheumatology|February 17, 2019
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop ReportAlí Duarte-García, Ying Ying Leung, Laura C Coates, et al.
The Patient|October 6, 2016
Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT)Maarten de Wit, John R Kirwan, Peter Tugwell, et al.
Pageof 44

Showing results (381-390 of 436) with videos related to

Sort By:
Pageof 44
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
The Journal of Rheumatology|March 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working GroupYing Ying Leung, Ana-Maria Orbai, William Tillett, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
The Journal of Rheumatology|December 17, 2018
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical TrialsAna-Maria Orbai, Richard Holland, Ying Ying Leung, et al.
Seminars in Arthritis and Rheumatism|September 8, 2021
Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 processDavid Roofeh, Shaney L Barratt, Athol U Wells, et al.
Annals of the Rheumatic Diseases|September 12, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)Roy M Fleischmann, Désirée van der Heijde, Vibeke Strand, et al.
The Journal of Rheumatology|February 17, 2019
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop ReportAlí Duarte-García, Ying Ying Leung, Laura C Coates, et al.
The Patient|October 6, 2016
Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT)Maarten de Wit, John R Kirwan, Peter Tugwell, et al.
Pageof 44